Bio-Connect

Twist1 antibody [N1C3]

GTX100621
GeneTex
ApplicationsWestern Blot
Product group Antibodies
TargetTWIST1
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    Twist1 antibody [N1C3]
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: 1:5000-1:20000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    Western Blot
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    1 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID7291
  • Target name
    TWIST1
  • Target description
    twist family bHLH transcription factor 1
  • Target synonyms
    ACS3, BPES2, BPES3, CRS, CRS1, CSO, SCS, SWCOS, TWIST, bHLHa38, twist-related protein 1, B-HLH DNA binding protein, H-twist, TWIST homolog of drosophila, class A basic helix-loop-helix protein 38, twist basic helix-loop-helix transcription factor 1, twist homolog 1
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDQ15672
  • Protein Name
    Twist-related protein 1
  • Scientific Description
    Basic helix-loop-helix (bHLH) transcription factors have been implicated in cell lineage determination and differentiation. The protein encoded by this gene is a bHLH transcription factor and shares similarity with another bHLH transcription factor, Dermo1. The strongest expression of this mRNA is in placental tissue; in adults, mesodermally derived tissues express this mRNA preferentially. Mutations in this gene have been found in patients with Saethre-Chotzen syndrome. [provided by RefSeq]
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • Lv F, Du Q, Li L, et al. Eriodictyol inhibits glioblastoma migration and invasion by reversing EMT via downregulation of the P38 MAPK/GSK-3β/ZEB1 pathway. Eur J Pharmacol. 2021,900:174069. doi: 10.1016/j.ejphar.2021.174069
    Read this paper
  • Lee AF, Chen MC, Chen CJ, et al. Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells. PLoS One. 2017,12(7):e0180383. doi: 10.1371/journal.pone.0180383
    Read this paper